Bio-Matrix' Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate(TM) Cell Therapy
Company Also Developing Two Solutions for Restoring Blood Production That Lack the Adverse Effects of Current Bone Marrow Stimulating Growth Factors
(firmenpresse) - SAN DIEGO, CA -- (Marketwire) -- 11/19/12 -- Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen's HemaXellerate™ product using mice models for testing. Cascade Life Sciences is a privately-owned San Diego-based company with a platform of stem cell related technologies that are being advanced to serve the research community and the commercial development of stem cell-based therapeutics. Sophia Khaldoyanidi, M.D., Ph.D. is the principal investigator of the study.
The results of Regen's study will provide the safety profile data required for filing of an Investigational New Drug (IND) application for the product with the US Food and Drug Administration . Regen intends to file an IND Application in the fourth quarter of 2012 and conduct Phase I/II clinical trials during 2013 and 2014.
HemaXellerate™ offers the possibility of delivering a population of endothelial cells to restore blood production in patients with hematological conditions. "Unlike current approaches of administering pharmaceuticals," said J. Christopher Mizer, President of Regen BioPharma, "our strategy is to heal the bone marrow by administering cells that provide the optimum mix of growth factors to stimulate the bone marrow into producing blood cells naturally."
Regen has submitted two provisional patent applications covering the use of different sources of endothelial cells to heal damaged bone marrow. These applications cover: (1) placental cells (61/648898 - Acceleration 0f Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells); and (2) fat cells (61/670791 - Treatment of Hematopoietic Disorders).
About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) is a biotechnology company developing regenerative medicine therapies. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.
Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. To follow our development, visit us at .
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks
Bio-Matrix Scientific Group, Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.11.2012 - 13:30 Uhr
Sprache: Deutsch
News-ID 204913
Anzahl Zeichen: 0
contact information:
Town:
SAN DIEGO, CA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 234 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bio-Matrix' Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate(TM) Cell Therapy"
steht unter der journalistisch-redaktionellen Verantwortung von
Bio-Matrix Scientific Group, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
